1.21% 0.59

アフターアワーズ： 49.63 0.10 +0.20%

Sanofi Adr (SNY)

概要ニュース株価時系列オプションチェーンなぜSNYが下落しているのか？ディスカッション予測株の配当実績

Sanofi Adr (SNY) 最新ニュース

Dec 04, 2025

Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm

Nov 21, 2025

Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends

Nov 21, 2025

A Technical View of the Leifras Co Ltd ADR (LFS) - fostersleader.com

Nov 21, 2025

Nov 17, 2025

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Nov 17, 2025

Nov 10, 2025

Why Roche Holding Stock Popped Today - Finviz

Nov 10, 2025

Nov 07, 2025

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz

Nov 07, 2025

Oct 28, 2025

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm

Oct 28, 2025

Oct 27, 2025

UPDATE - GlobeNewswire Inc.

Oct 27, 2025

Oct 24, 2025

Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria

Oct 24, 2025

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm

Oct 24, 2025

Oct 22, 2025

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm

Oct 22, 2025

Oct 17, 2025

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm

Oct 17, 2025

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm

Oct 17, 2025

Oct 16, 2025

Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail

Oct 16, 2025

Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail

Oct 16, 2025

Oct 14, 2025

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm

Oct 14, 2025

Oct 11, 2025

SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent

Oct 11, 2025

Oct 04, 2025

UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail

Oct 04, 2025

Oct 02, 2025

Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail

Oct 02, 2025

Sep 29, 2025

BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals

Sep 29, 2025

Sep 26, 2025

Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm

Sep 26, 2025

Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm

Sep 26, 2025

PFE

$26.03

1.28%

GILD

$121.22

0.98%

AMGN

$329.89

3.07%

NVO

$47.86

0.27%

MRK

$99.72

1.16%

Sanofi Adr (SNY)

Sanofi Adr (SNY) 最新ニュース

Press Release: Sanofi completes acquisition of Vicebio - GlobeNewswire Inc.

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe - Sahm

Bloom Energy-Aktie: Vorsicht geboten! - Finanztrends

Abbott-Aktie: 21 Milliarden Dollar für neues Wachstum! - Finanztrends

Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm

Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends

A Technical View of the Leifras Co Ltd ADR (LFS) - fostersleader.com

Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Why Roche Holding Stock Popped Today - Finviz

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm

UPDATE - GlobeNewswire Inc.

Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm

Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail

Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm

SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent

UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail

Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail

BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals

Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm

Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm

SNYに似た銘柄